Anaphase-promoting complex

Anaphase-promoting complex
Name	Anaphase-promoting complex
Organism	Eukaryota
Symbols	APC/C

Anaphase-promoting complex is a multi-subunit E3 ubiquitin ligase that orchestrates progression through mitosis by targeting key cell cycle regulators for proteasomal degradation. It integrates signals from checkpoints to ensure chromosomal stability and coordinates transitions between metaphase and anaphase, interacting with numerous proteins and pathways conserved across eukaryotes. The complex is central to studies in cell biology, cancer research, developmental biology, and proteostasis.

Structure and subunits

The complex is composed of a scaffold of large subunits and multiple catalytic and regulatory components distributed into distinct subcomplexes; structural characterization has involved cryo-electron microscopy studies comparable to those used for Ribosome and Proteasome (prokaryotic) analyses and has benefitted from collaborations among groups at institutions such as Max Planck Society and Cold Spring Harbor Laboratory. Core subunits include cullin-like and tetratricopeptide repeat-containing proteins analogous to components found in SCF complex and complexes studied by researchers at Howard Hughes Medical Institute, with named subunits often designated by gene symbols that were mapped in genetic screens conducted in model organisms like Saccharomyces cerevisiae, Drosophila melanogaster, and Xenopus laevis. High-resolution maps reveal interactions between scaffold subunits and catalytic modules reminiscent of architectures in E3 ubiquitin-protein ligase RBX1 complexes and informed by methods developed at European Molecular Biology Laboratory and National Institutes of Health centers. Many subunits are conserved from yeast to human, with functional homologs identified in studies from laboratories at University of Cambridge, Harvard University, and University of Tokyo.

Regulation and activation

Activation depends on association with co-activator proteins whose identification followed genetic and biochemical work by groups at Stanford University and University of California, San Francisco. Co-activators bind in a cell-cycle-dependent manner similar to regulatory interactions characterized for Cyclin-dependent kinase 1 and Cyclin B1, and are modulated by post-translational modifications studied in labs at MIT and Yale University. Checkpoint proteins from the spindle assembly checkpoint, identified through screens at The Rockefeller University and Columbia University, inhibit activation until proper kinetochore attachment is achieved; this inhibition parallels mechanisms elucidated for regulatory circuits investigated at Princeton University. Phosphorylation by mitotic kinases such as Polo-like kinase 1 and Aurora B kinase and interactions with checkpoint proteins akin to findings from Wellcome Trust Sanger Institute research facilitate the transition from an inhibited to an active state, a regulatory theme also observed in signaling networks characterized at Broad Institute.

Mechanism of ubiquitination and substrates

The complex functions as a RING-type E3 ligase that recruits E2 ubiquitin-conjugating enzymes in a process mechanistically related to ubiquitination pathways dissected at European Molecular Biology Organization conferences; this recruitment promotes transfer of ubiquitin to lysine residues on substrates in manners comparable to mechanisms defined for MDM2 and APC/C coactivators studied in multiple centers including Johns Hopkins University. Canonical substrates include securin and mitotic cyclins, targets identified in landmark experiments from groups at Rockefeller University and Cold Spring Harbor Laboratory, and substrate recognition involves degron motifs analogous to the destruction box characterized in research from Max Planck Institute for Molecular Genetics and sequence determinants mapped by teams at University of Geneva. Ubiquitin chain topology and processivity have been characterized using biochemical reconstitution approaches pioneered at University of California, Berkeley and ETH Zurich, revealing regulation of substrate fate that informs proteasome-mediated degradation studied at Fred Hutchinson Cancer Center.

Role in cell cycle and mitosis

Functionally, the complex triggers anaphase onset and mitotic exit by degrading inhibitors of chromatid separation, roles that were defined in classical cell cycle studies from Nobel Prize in Physiology or Medicine-linked research groups and continued by laboratories at Stanford University School of Medicine. Its timing and activity are coordinated with checkpoints and mitotic spindle dynamics addressed in work from European Organization for Nuclear Research and Max Planck Institute for Biophysical Chemistry, ensuring fidelity of chromosome segregation as emphasized in seminars at Cold Spring Harbor Laboratory. Genetic perturbation experiments in Caenorhabditis elegans, Drosophila melanogaster, and mammalian systems carried out at institutions including University of California, San Diego and University of Oxford demonstrate conserved essentiality for cell cycle transitions and embryonic development.

Biological functions beyond mitosis

Beyond mitotic control, the complex participates in processes such as meiotic progression, neuronal differentiation, synaptic plasticity, and cellular metabolism, parallels drawn with regulatory roles documented for p53 and Notch signaling pathway components by research teams at University of Pennsylvania and Cold Spring Harbor Laboratory. Roles in developmental timing and morphogenesis have been elucidated in model organism studies from Max Planck Institute for Developmental Biology and European Molecular Biology Laboratory, while links to circadian regulation and stem cell maintenance have been explored in consortia including researchers from Karolinska Institute and Broad Institute.

Clinical significance and disease associations

Aberrant regulation or mutation of complex subunits and regulators is implicated in oncogenesis, neurodegenerative diseases, and congenital disorders; cancer associations were revealed in genomic studies from The Cancer Genome Atlas and translational research at Memorial Sloan Kettering Cancer Center. Therapeutic strategies targeting its regulators or modulating ubiquitination dynamics are under investigation by pharmaceutical efforts at Pfizer, Novartis, and academic spinouts from University of Cambridge and MIT. Mutations affecting ubiquitin pathway components have clinical relevance comparable to findings in inherited disorders characterized by groups at Mayo Clinic and Johns Hopkins Hospital, motivating biomarker and drug-discovery programs at National Cancer Institute and industry partnerships with GlaxoSmithKline.

Category:Cell cycle